newscontact us

TotipotentRX and ThermoGenesis Achieve Bone Marrow Stem Cell Transplant Milestone

Twentieth Patient Transplanted at the Fortis Memorial Research Institute (“FMRI”)

RANCHO CORDOVA, Calif., LOS ANGELES and NEW DELHI, India, Feb. 3, 2014 (GLOBE NEWSWIRE) — ThermoGenesis Corp. (Nasdaq:KOOL) a cellular therapy medical device company and TotipotentRX Corporation, a clinical-stage regenerative medicine company developing novel therapies for cardiovascular and orthopedic disease, announced the TotiPotentRX cellular therapy clinical team in partnership with Fortis Healthcare, Gurgaon (New Delhi) has achieved its 20th pediatric bone marrow transplant (BMT). This haploidentical BMT was performed from a mother as a donor for a 10 year old child suffering from combined immunodeficiency due to a DOCK-8 gene mutation. The Fortis Centre has so far performed 15 allogenetic BMT including five haploidentical and one double unrelated cord blood transplants, and 5 autologous transplants. This transplant was completed on February 1, 2014 at the Pediatric Hematology and Bone Marrow Transplant department led by Dr. Satya Yadav, M.D., Head of the Department for Pediatric Hematology and Bone Marrow Transplant, and with scientific and laboratory support by the TotipotentRX’s cell therapy GMP laboratory facility. This 20th transplant is a significant milestone in the pursuit of developing the new FMRI BMT program into one of the leading stem cell transplant centers in Asia.

020314 Bone Marrow Stem Cell Transplant Milestone Final